Rushmore Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Rushmore Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$1.78M	Buy	+19,324	New	+$1.86M	0.36%	85

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Rushmore Investment Advisors's ALXN Position: Q2 2013 in Review

Rushmore Investment Advisors opened a new position in Alexion Pharmaceuticals (ALXN) in Q2 2013: 19,324 shares worth $1.78M. The stake represents 0.36% of the portfolio and ranks #85 among its holdings.

406 funds tracked by Wall St. Rank hold ALXN as of Q2 2013.

Rushmore Investment Advisors held 19,324 shares of Alexion Pharmaceuticals worth $1.78M as of Q2 2013.
Alexion Pharmaceuticals was a new Rushmore Investment Advisors position in Q2 2013.
Alexion Pharmaceuticals made up 0.36% of Rushmore Investment Advisors's portfolio in Q2 2013, its #85 holding.
406 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2013.

Based on Rushmore Investment Advisors's 13F filing for Q2 2013, filed 29 Aug 2013.